• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Biote Corp.

    4/3/25 4:56:01 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTMD alert in real time by email
    DEFA14A 1 d917136ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.   )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to § 240.14a-12

    BIOTE CORP.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


    LOGO    LOGO

    biote Corp.

     

    Annual Meeting of Stockholders

     

    Tuesday, May 13, 2025 10:00 AM, Central Time

     

    Annual Meeting to be held live via the internet - please visit www.proxydocs.com/BTMD for more details.

     

    You must register to attend the Annual Meeting online and/or participate at www.proxydocs.com/BTMD

     

     

    For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/BTMD

     

    To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

     

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

     

    If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 2, 2025.

     

      

    LOGO

     

      

     

     

    Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K

     

    Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On May 13, 2025 For Stockholders of record as of March 24, 2025

     

    To order paper materials, use one of the following methods.

     

      LOGO

     

    Internet:

    www.investorelections.com/BTMD

     

      LOGO

    Call:

    1-866-648-8133

     

      LOGO

    Email:

    [email protected]

     

    * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

     

    LOGO

         

    Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

    SEE REVERSE FOR FULL AGENDA      

    Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved   


    LOGO   biote Corp. Annual Meeting of Stockholders

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

    FOR ALL NOMINEES FOR DIRECTOR IN PROPOSAL 1 AND FOR PROPOSAL 2

     

     

     

    PROPOSAL

     

    1.    To elect two Class III directors, each to serve until our 2028 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal;   
       1.01 Marc Beer   
       1.02 Bret Christensen   
    2.    To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;   
       Note: To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
    Get the next $BTMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTMD

    DatePrice TargetRatingAnalyst
    8/7/2025$4.00Buy → Neutral
    B. Riley Securities
    12/16/2024Buy
    Craig Hallum
    2/20/2024$9.00Buy
    B. Riley Securities
    2/1/2024Buy
    Jefferies
    More analyst ratings

    $BTMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    biote Corp. downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded biote Corp. from Buy to Neutral and set a new price target of $4.00

    8/7/25 7:36:54 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on biote Corp.

    Craig Hallum initiated coverage of biote Corp. with a rating of Buy

    12/16/24 8:50:55 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    B. Riley Securities initiated coverage on biote Corp. with a new price target

    B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00

    2/20/24 6:47:29 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/8/25 7:16:54 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/2/25 5:12:33 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    4/23/25 4:58:23 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    SEC Filings

    View All

    SEC Form 8-K filed by Biote Corp.

    8-K - biote Corp. (0001819253) (Filer)

    1/26/26 5:21:27 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Biote Corp.

    10-Q - biote Corp. (0001819253) (Filer)

    11/7/25 4:05:33 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - biote Corp. (0001819253) (Filer)

    11/5/25 4:08:13 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biote Reports Third Quarter 2025 Financial Results

    Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025 financial guidance Third Quarter 2025 Financial Highlights Revenue of $48.0 million Gross profit margin of 71.8% Net income of $9.2 million and diluted earnings per share attributable to biote Corp. stockholders of $0.22, compared to net income of $12.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.33 in the prior year period Adjusted EBITDA1 of $12.9 million and Adjusted EBITDA margin1 of 26.9% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the heal

    11/5/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast w

    10/22/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Reports Second Quarter 2025 Financial Results

    Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote for sustainable long-term growth and value creation Second Quarter 2025 Financial Highlights Revenue of $48.9 million Gross profit margin of 71.6% Net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to net loss of $(10.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.21) in the prior year period Adjusted EBITDA1 of $15.2 million and Adjusted EBITDA margin1 of 31.1% Bio

    8/6/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Barrera Richard R

    4 - biote Corp. (0001819253) (Issuer)

    6/11/25 6:54:32 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Morris Debra L converted options into 11,045 shares, increasing direct ownership by 28% to 50,155 units (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/15/25 11:26:51 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Heyer Steven J

    4 - biote Corp. (0001819253) (Issuer)

    5/14/25 7:42:41 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Financials

    Live finance-specific insights

    View All

    Biote Reports Third Quarter 2025 Financial Results

    Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025 financial guidance Third Quarter 2025 Financial Highlights Revenue of $48.0 million Gross profit margin of 71.8% Net income of $9.2 million and diluted earnings per share attributable to biote Corp. stockholders of $0.22, compared to net income of $12.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.33 in the prior year period Adjusted EBITDA1 of $12.9 million and Adjusted EBITDA margin1 of 26.9% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the heal

    11/5/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast w

    10/22/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Reports Second Quarter 2025 Financial Results

    Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote for sustainable long-term growth and value creation Second Quarter 2025 Financial Highlights Revenue of $48.9 million Gross profit margin of 71.6% Net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to net loss of $(10.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.21) in the prior year period Adjusted EBITDA1 of $15.2 million and Adjusted EBITDA margin1 of 31.1% Bio

    8/6/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Leadership Updates

    Live Leadership Updates

    View All

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Biote to Purchase Asteria Health

    Strategic and accretive transaction enables vertical integration of hormone product manufacturing biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states. Through this transaction, Biote is strengt

    1/17/24 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Names Robert Peterson as Chief Financial Officer

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar's transition is unrelated to t

    1/11/24 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biote Corp.

    SC 13G/A - biote Corp. (0001819253) (Subject)

    11/12/24 4:15:18 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Biote Corp. (Amendment)

    SC 13G/A - biote Corp. (0001819253) (Subject)

    2/14/24 5:17:02 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Biote Corp. (Amendment)

    SC 13G/A - biote Corp. (0001819253) (Subject)

    2/14/24 2:11:05 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care